• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Merus N.V.

    12/12/25 8:00:24 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    S-8 POS 1 d26669ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on December 12, 2025

    Registration No. 333-211497

    Registration No. 333-230708

    Registration No. 333-254345

    Registration No. 333-277468

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-211497

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-230708

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-254345

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-277468

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Merus N.V.

    (Exact name of registrant as specified in its charter)

     

     

     

    The Netherlands   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Uppsalalaan 17

    3rd and 4th Floor

    3584 CT Utrecht

    The Netherlands

      Not Applicable
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    MERUS N.V. 2010 EMPLOYEE OPTION PLAN

    MERUS N.V. 2016 INCENTIVE AWARD PLAN

    (Full titles of the plans)

    Genmab US, Inc.

    777 Scudders Mill Road

    Plainsboro, NJ 08536

    (609) 430-2481

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    With a copy to:

    Harald Halbhuber

    Clare O’Brien

    Derrick Lott

    Allen Overy Shearman Sterling US LLP

    599 Lexington Avenue

    New York, New York 10022-6069

    Telephone: (212) 848-4000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. Yes ☐ No ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    These post-effective amendments (the “Post-Effective Amendments”), filed by Merus N.V., a public limited liability company organized under the laws of the Netherlands (the “Company”), remove from registration all common shares, nominal value €0.09 per share, of the Company (the “Common Shares”) previously registered under the following Registration Statements on Form S-8 filed by the Company (the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “SEC”) pertaining to the registration of Common Shares.

     

      •  

    Registration No. 333-211497, which was previously filed with the SEC on May 20, 2016, registering 966,690 Common Shares under the Merus N.V. 2010 Employee Option Plan and 2,576,347 Common Shares under the Merus N.V. 2016 Incentive Award Plan;

     

      •  

    Registration No. 333-230708, which was previously filed with the SEC on April 3, 2019, registering 1,868,718 Common Shares under the Merus N.V. 2016 Incentive Award Plan;

     

      •  

    Registration No. 333-254345, which was previously filed with the SEC on March 16, 2021, registering 2,419,406 Common Shares under the Merus N.V. 2016 Incentive Award Plan; and

     

      •  

    Registration No. 333-277468, which was previously filed with the SEC on February 28, 2024, registering 9,534,386 Common Shares under the Merus N.V. 2016 Incentive Award Plan.

    On September 29, 2025, the Company entered into a Transaction Agreement (the “Transaction Agreement”) with Genmab A/S, a public limited liability company (Aktieselskab) organized under the Laws of Denmark (“Parent”) and Genmab Holding II B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) organized under the Laws of The Netherlands and a wholly owned subsidiary of Parent (“Purchaser”), to purchase all of the issued and outstanding Common Shares of the Company in exchange for $97.00 per Common Share in cash (the “Offer Consideration”), without interest and subject to any applicable tax withholding, on the terms and subject to the conditions set forth in the offer to purchase, dated October 21, 2025 (as it may be amended, supplemented or otherwise modified from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be amended, supplemented or otherwise modified from time to time, constitute the “Offer”). On December 11, 2025, pursuant to the Transaction Agreement, Purchaser completed its initial tender offer for all of the Company’s outstanding Common Shares and accepted for payment approximately 94.2% of the issued and outstanding Common Shares (the “Closing”).

    As a result of the Closing, the Company has terminated all offerings of the Company’s securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all plan interests and any and all securities registered for issuance under the Registration Statements that remain unsold as of the date hereof. This filing is made in accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance that remain unsold at the termination of the offering.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Copenhagen, Denmark on this 12th day of December, 2025.

     

    MERUS N.V.
    By:  

    /s/ Jan G. J. van de Winkel

      Name: Jan G. J. van de Winkel
      Title: Chief Executive Officer

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this Post-Effective Amendment, in the City of Copenhagen, Denmark in this 12th day of December, 2025.

     

    Authorized Representative in the United States
    By:  

    /s/ Anthony Pagano

      Name:   Anthony Pagano
      Title:   Authorized Representative
    Get the next $MRUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    9/17/2025$112.00Overweight
    Barclays
    8/25/2025$90.00Buy
    Alliance Global Partners
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    More analyst ratings

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer & PFO Perry Gregory D

    4 - Merus N.V. (0001651311) (Issuer)

    12/12/25 7:09:47 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mehra Anand

    4 - Merus N.V. (0001651311) (Issuer)

    12/12/25 7:05:10 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kanavy Len

    4 - Merus N.V. (0001651311) (Issuer)

    12/12/25 7:04:23 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    SEC Filings

    View All

    SEC Form S-8 POS filed by Merus N.V.

    S-8 POS - Merus N.V. (0001651311) (Filer)

    12/12/25 8:02:34 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Merus N.V.

    S-8 POS - Merus N.V. (0001651311) (Filer)

    12/12/25 8:01:37 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Merus N.V.

    S-8 POS - Merus N.V. (0001651311) (Filer)

    12/12/25 8:00:24 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Merus with a new price target

    Barclays initiated coverage of Merus with a rating of Overweight and set a new price target of $112.00

    9/17/25 8:02:58 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Merus with a new price target

    Alliance Global Partners initiated coverage of Merus with a rating of Buy and set a new price target of $90.00

    8/25/25 7:58:18 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Merus with a new price target

    Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

    2/13/25 8:09:56 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

    Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of 2029   Genmab A/S (NASDAQ:GMAB) ("Genmab") announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the "Offer") by Genmab Holding II B.V., a wholly owned subsidiary of Genmab ("Purchaser"), to acquire all the issued and outstanding common shares of Merus N.V. (NASDAQ:MRUS) ("Merus") for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shift to a wholly owned model, expa

    12/12/25 1:36:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

    Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolioTransaction anticipated to be accretive to Genmab's EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (NASDAQ:GMAB) ("Genmab") announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the "Offer") by Genmab Holding II B.V., a wholly owned subsidiary of Genmab ("Purchaser"), to acquire all the issued and outstanding common shares of Merus N.V. (NASDAQ:MRUS) ("Merus") for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shi

    12/12/25 1:35:27 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

    SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (NASDAQ:MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme"), a leader in subcutaneous drug delivery solutions, today announced they have entered into a global non-exclusive collaboration and license agreement. Under the collaboration, Merus has licensed Halozyme's ENHANZE® drug delivery technology, for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecif

    11/17/25 7:00:00 AM ET
    $HALO
    $MRUS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MRUS
    Financials

    Live finance-specific insights

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

    -  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be

    5/22/25 5:30:00 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 4:05:20 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 1:34:01 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 8:54:46 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    View All

    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

    7/1/24 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

    6/15/23 7:47:06 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

    1/25/22 4:30:00 PM ET
    $INCY
    $MRUS
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations